NEW! Second-Line CAR T-Cell Therapy for Multiple Myeloma

Check out the new educator module on Second-Line CAR T-Cell Therapy for Multiple Myeloma,  presented by Michelle Lauer, PA-C, MPH, of Stanford Health Care, provides a comprehensive overview of the CARTITUDE-4 study data, which led to FDA approval of ciltacabtagene autoleucel in the second line for patients with relapsed/refractory multiple myeloma. Ms. Lauer discusses appropriate identification of good candidates for second-line CAR T-cell therapy, barriers to treatment, and incidence and management of associated toxicities.

Explore Here

Funding and support provided by Johnson & Johnson and Legend Biotech.